MA54248A - Régulation de métaux traces pendant la production d'anticorps anti-cd38 - Google Patents
Régulation de métaux traces pendant la production d'anticorps anti-cd38Info
- Publication number
- MA54248A MA54248A MA054248A MA54248A MA54248A MA 54248 A MA54248 A MA 54248A MA 054248 A MA054248 A MA 054248A MA 54248 A MA54248 A MA 54248A MA 54248 A MA54248 A MA 54248A
- Authority
- MA
- Morocco
- Prior art keywords
- regulation
- antibody production
- trace metals
- during anti
- metals during
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
- C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862760782P | 2018-11-13 | 2018-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54248A true MA54248A (fr) | 2021-09-22 |
Family
ID=70551717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054248A MA54248A (fr) | 2018-11-13 | 2019-11-13 | Régulation de métaux traces pendant la production d'anticorps anti-cd38 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11634499B2 (fr) |
| EP (2) | EP3880824B1 (fr) |
| JP (2) | JP7599418B2 (fr) |
| KR (2) | KR20260096881A (fr) |
| CN (1) | CN113015805B (fr) |
| AU (1) | AU2019379858B2 (fr) |
| CA (1) | CA3117447C (fr) |
| EA (1) | EA202191352A1 (fr) |
| ES (1) | ES2994759T3 (fr) |
| IL (1) | IL282970A (fr) |
| MA (1) | MA54248A (fr) |
| MX (1) | MX2021005611A (fr) |
| SG (1) | SG11202104092UA (fr) |
| TW (1) | TW202039849A (fr) |
| WO (1) | WO2020100073A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| PE20171094A1 (es) | 2014-12-04 | 2017-08-07 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda |
| CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| JP7027321B2 (ja) * | 2015-11-03 | 2022-03-01 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ３８抗体の皮下製剤及びその使用 |
| WO2018002181A1 (fr) | 2016-06-28 | 2018-01-04 | Umc Utrecht Holding B.V. | Traitement de maladies médiées par l'ige avec des anticorps qui se lient spécifiquement à cd38 |
| CN113015805B (zh) | 2018-11-13 | 2024-12-03 | 詹森生物科技公司 | 抗cd38抗体产生期间的痕量金属的控制 |
| CN119371539A (zh) * | 2024-12-05 | 2025-01-28 | 齐鲁制药有限公司 | 用于生产抗cd38抗体的方法 |
| CN122430558A (zh) * | 2026-06-22 | 2026-07-21 | 江苏先思达生物科技有限公司 | 一种用于识别弥漫大b细胞淋巴瘤的指标组合及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4072565A (en) | 1974-11-04 | 1978-02-07 | The Dow Chemical Company | Production of viruses in tissue culture without use of serum |
| EP0082974B1 (fr) | 1981-12-24 | 1986-05-14 | Asahi Kasei Kogyo Kabushiki Kaisha | Procédé de culture de cellules diploides normales et milieu de culture utilisé â cet effet |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| FR2543158B1 (fr) | 1983-03-24 | 1985-11-15 | Inst Nat Sante Rech Med | Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu |
| EP0281604B1 (fr) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Molecules de liaison de chaines de polypeptide simples |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5856179A (en) | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| US6656466B1 (en) | 1995-06-06 | 2003-12-02 | Genetech, Inc. | Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition |
| JP4306813B2 (ja) | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | 動物細胞の新規培養方法 |
| US5804420A (en) | 1997-04-18 | 1998-09-08 | Bayer Corporation | Preparation of recombinant Factor VIII in a protein free medium |
| US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
| US6528286B1 (en) | 1998-05-29 | 2003-03-04 | Genentech, Inc. | Mammalian cell culture process for producing glycoproteins |
| US6924124B1 (en) | 2002-08-23 | 2005-08-02 | Immunex Corporation | Feeding strategies for cell culture |
| EP2330213A1 (fr) | 2003-03-05 | 2011-06-08 | Halozyme, Inc. | Glycoprotéine d'hyaluronidase soluble (sHASEGP), son procédé de préparation, utilisations et compositions pharmaceutiques le comportant |
| DE602004027905D1 (de) | 2003-05-15 | 2010-08-12 | Wyeth Llc | Kontrollierte glukosezufuhr für tierzellkultur |
| US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| EP2551282A3 (fr) | 2005-03-23 | 2013-02-13 | Genmab A/S | Anticorps diriges contre CD38 pour le traitement du myelome multiple |
| CN101287764B (zh) | 2005-10-12 | 2013-11-13 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| ES2474573T3 (es) | 2006-01-04 | 2014-07-09 | Baxter International Inc | Medio de cultivo celular sin oligop�ptidos |
| DK2041270T3 (da) | 2006-07-13 | 2014-01-27 | Wyeth Llc | Fremstilling af glycoproteiner |
| EP1914242A1 (fr) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Nouveau anticorps Anti-CD38 pour le traitement du cancer |
| US20090076249A1 (en) * | 2007-09-19 | 2009-03-19 | Michel De Weers | Antibodies against CD38 for treatment of multiple myeloma |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| WO2012149197A2 (fr) * | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante |
| JP6480926B2 (ja) | 2013-07-23 | 2019-03-13 | バイオコン・リミテッド | タンパク質におけるフコシル化レベルを制御するための方法 |
| US20150139988A1 (en) * | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| RS59881B1 (sr) * | 2014-02-27 | 2020-03-31 | Hoffmann La Roche | Modulacija ćelijskog rasta i glikozilacije u rekombinantnoj proizvodnji glikoproteina |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| KR101660580B1 (ko) | 2014-04-02 | 2016-09-28 | 프레스티지 바이오파마 피티이. 엘티디. | 항체의 당 함량 조절을 통한 항체의 제조 방법 |
| BR112016023769A2 (pt) * | 2014-04-17 | 2017-10-17 | Boehringer Ingelheim Rcv Gmbh | célula hospedeira recombinante para a expressão de proteínas de interesse |
| CA2969225C (fr) | 2014-12-01 | 2023-08-22 | Amgen Inc. | Procede de manipulation du taux de contenu de glycane d'une glycoproteine |
| EP3072957B1 (fr) * | 2015-03-23 | 2019-07-10 | Lonza Ltd | Procédés permettant de réguler la glycosylation de protéines |
| WO2016196621A1 (fr) | 2015-06-01 | 2016-12-08 | Biogen Ma Inc. | Supplémentation en manganèse pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère |
| JP7027321B2 (ja) | 2015-11-03 | 2022-03-01 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ３８抗体の皮下製剤及びその使用 |
| CN113015805B (zh) | 2018-11-13 | 2024-12-03 | 詹森生物科技公司 | 抗cd38抗体产生期间的痕量金属的控制 |
-
2019
- 2019-11-13 CN CN201980074932.1A patent/CN113015805B/zh active Active
- 2019-11-13 MX MX2021005611A patent/MX2021005611A/es unknown
- 2019-11-13 WO PCT/IB2019/059766 patent/WO2020100073A1/fr not_active Ceased
- 2019-11-13 KR KR1020267018750A patent/KR20260096881A/ko active Pending
- 2019-11-13 EP EP19885702.1A patent/EP3880824B1/fr active Active
- 2019-11-13 US US16/682,551 patent/US11634499B2/en active Active
- 2019-11-13 EA EA202191352A patent/EA202191352A1/ru unknown
- 2019-11-13 ES ES19885702T patent/ES2994759T3/es active Active
- 2019-11-13 SG SG11202104092UA patent/SG11202104092UA/en unknown
- 2019-11-13 JP JP2021525797A patent/JP7599418B2/ja active Active
- 2019-11-13 KR KR1020217017776A patent/KR20210091763A/ko active Pending
- 2019-11-13 MA MA054248A patent/MA54248A/fr unknown
- 2019-11-13 CA CA3117447A patent/CA3117447C/fr active Active
- 2019-11-13 TW TW108141240A patent/TW202039849A/zh unknown
- 2019-11-13 AU AU2019379858A patent/AU2019379858B2/en active Active
- 2019-11-13 EP EP24190303.8A patent/EP4461310A3/fr active Pending
-
2021
- 2021-05-05 IL IL282970A patent/IL282970A/en unknown
-
2024
- 2024-05-30 JP JP2024087951A patent/JP2024129019A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210091763A (ko) | 2021-07-22 |
| EP3880824B1 (fr) | 2024-07-24 |
| BR112021008879A2 (pt) | 2021-10-26 |
| SG11202104092UA (en) | 2021-05-28 |
| JP2024129019A (ja) | 2024-09-26 |
| MX2021005611A (es) | 2021-06-30 |
| CN113015805A (zh) | 2021-06-22 |
| KR20260096881A (ko) | 2026-06-24 |
| CA3117447A1 (fr) | 2020-05-22 |
| JP2022513018A (ja) | 2022-02-07 |
| EP4461310A2 (fr) | 2024-11-13 |
| US11634499B2 (en) | 2023-04-25 |
| WO2020100073A1 (fr) | 2020-05-22 |
| IL282970A (en) | 2021-06-30 |
| EP3880824A1 (fr) | 2021-09-22 |
| AU2019379858A1 (en) | 2021-05-20 |
| AU2019379858B2 (en) | 2024-01-04 |
| CA3117447C (fr) | 2024-06-04 |
| EP3880824A4 (fr) | 2022-08-10 |
| TW202039849A (zh) | 2020-11-01 |
| EA202191352A1 (ru) | 2021-08-11 |
| US20200148782A1 (en) | 2020-05-14 |
| ES2994759T3 (en) | 2025-01-30 |
| JP7599418B2 (ja) | 2024-12-13 |
| CN113015805B (zh) | 2024-12-03 |
| EP4461310A3 (fr) | 2025-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3880824A4 (fr) | Régulation de métaux traces pendant la production d'anticorps anti-cd38 | |
| EP3677589A4 (fr) | Procédé amélioré de production d'un conjugué anticorps-médicament | |
| MA50169A (fr) | Procédé de production d'un électrocatalyseur | |
| EP3679011A4 (fr) | Composés amide et nitrile et procédés de production et d'utilisation de ceux-ci | |
| EP3677568A4 (fr) | Nouveau procédé de production d'un conjugué anticorps-médicament | |
| EP3294865A4 (fr) | Procédés de production d'épimérases et d'alcaloïdes benzylisoquinoléine | |
| MA50859A (fr) | Procédé pour la production d'une composition de lymphocytes t | |
| EP3368238A4 (fr) | Procédés de fabrication d'atomisation de poudre métallique | |
| EP3822000A4 (fr) | Poudre d'alliage et son procédé de production | |
| EP3411476A4 (fr) | Production améliorée d'immunoglobulines | |
| EP3604513A4 (fr) | Composition pour la production de tagatose et procédé de production de tagatose l'utilisant | |
| EP3341485A4 (fr) | Production améliorée d'immunoglobulines | |
| EP3897717A4 (fr) | Procédés de production d'anticorps hétérodimères | |
| EP3397602A4 (fr) | Procédé d'oxydation pour la production de thiosulfate de potassium | |
| EP3734268A4 (fr) | Procédé simplifié de quantification d'anticorps monoclonaux | |
| EP3611171A4 (fr) | Procédé de synthèse d'éliglustat et de composés intermédiaires de celui-ci | |
| EP3459659A4 (fr) | Poudre d'alliage et procédé de préparation associé | |
| EP3825002C0 (fr) | Appareil pour la fabrication d'un support de catalyseur métallique | |
| EP3647316A4 (fr) | Procédé de production d'édulcorant à base d'allulose | |
| EP3838451A4 (fr) | Procédé de production de poudre métallique atomisée à l'eau | |
| EP3712194A4 (fr) | Procédé de production de polyamide avec addition régulée d'activateur, et polyamide ainsi produit | |
| EP3901123A4 (fr) | Procédé de production de fluoro-éthane et procédé de production d'une fluoro-oléfine | |
| EP3802893A4 (fr) | Procédés de production de poudres métalliques fines à partir de composés métalliques | |
| EP3947409A4 (fr) | Production biosynthétique d'udp-rhamnose | |
| EP3677572C0 (fr) | Procédé de production d'un dérivé de pyrazole-4-carboxamide |